TY - JOUR AU - Fauziah, Nisa AU - Koesoemadinata, Raspati C AU - Andriyoko, Basti AU - Faridah, Lia AU - Riswari, Silvita F AU - Widyatmoko, Leonardus AU - Prihatni, Delita AU - Ekawardhani, Savira AU - Fibriani, Azzania AU - Rachmawati, Emma AU - Ristandi, Ryan B AU - Alamanda, Cut NC AU - Prodjosoewojo, Susantina AU - Lestari, Bony W AU - Santoso, Ida P PY - 2021/03/07 Y2 - 2024/03/29 TI - The performance of point-of-care antibody test for COVID-19 diagnosis in a tertiary hospital in Bandung, Indonesia JF - The Journal of Infection in Developing Countries JA - J Infect Dev Ctries VL - 15 IS - 02 SE - Coronavirus Pandemic DO - 10.3855/jidc.13370 UR - https://www.jidc.org/index.php/journal/article/view/33690206 SP - 237-241 AB - <p>Introduction: We aim to describe the performance of combined IgM and IgG point-of-care antibody test (POC-Ab) (Wondfo®) compared to real-time reverse transcriptase (rRT-PCR) (Allplex™ 2019-nCoV Assay) in detecting coronavirus disease 2019 (COVID-19).</p><p>Methodology: We compared POC-Ab with rRT-PCR results among patients in a tertiary hospital from January to March 2020 in Bandung, Indonesia. We selected presumptive COVID-19 patients with positive rRT-PCR consecutively and 20 patients with negative rRT-PCR results were selected randomly from the same group of patients as controls. We described the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) with corresponding 95% confidence interval using serum and capillary blood samples. We also tested POC-Ab using non-COVID-19 (confirmed dengue and typhoid) patients’ sera.</p><p>Results: Twenty-seven patients with positive rRT-PCR result and 20 negative controls were included (68.1% males, mean age 46 (SD: 15.4)). Using the serum, the sensitivity of the POC-Ab was 63.0% (42.4-80.6), specificity was 95.0% (75.1-99.9), PPV was 94.4% (72.7-99.8), NPV was 65.5% (45.7-82.1). A subset of 20 patients was tested using a capillary blood sample. The accuracy of the capillary blood sample is lower compared to serum (50.0% vs. 78.7%). None of the non-COVID-19 sera tested were reactive.</p><p>Conclusions: POC-Ab for COVID-19 has a high specificity with no false-positive result in non-COVID-19 sera. Therefore, it can be used to guide diagnostic among symptomatic patients in resource limited settings. Given its low sensitivity, patients with high suspicion of COVID-19 but non-reactive result should be prioritized for rRT-PCR testing.</p> ER -